NO20083416L - Peptidsekvenser og preparater - Google Patents

Peptidsekvenser og preparater

Info

Publication number: NO20083416L
Authority: NO; Norway
Prior art keywords: polypeptide; seq; preparations; peptide sequences; epitope
Prior art date: 2006-02-07

Application number

NO20083416A

Other languages

English (en)

Norwegian (no)

Inventor

Alan Gregory Stoloff

Romero Wilson Caparros-Wanderley

Original Assignee

Peptcell Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-02-07

Filing date

2008-08-04

Publication date

2008-11-07

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38109631&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20083416(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2006-02-07 Priority claimed from GB0602416A external-priority patent/GB0602416D0/en

2008-08-04 Application filed by Peptcell Ltd filed Critical Peptcell Ltd

2008-11-07 Publication of NO20083416L publication Critical patent/NO20083416L/no

Links

108090000765 processed proteins & peptides Proteins 0.000 title abstract 5
238000002360 preparation method Methods 0.000 title 1
229920001184 polypeptide Polymers 0.000 abstract 4
102000004196 processed proteins & peptides Human genes 0.000 abstract 4
108700018351 Major Histocompatibility Complex Proteins 0.000 abstract 2
150000001413 amino acids Chemical class 0.000 abstract 2
230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 abstract 2
108700028369 Alleles Proteins 0.000 abstract 1
241000251539 Vertebrata <Metazoa> Species 0.000 abstract 1
230000002163 immunogen Effects 0.000 abstract 1
241000712461 unidentified influenza virus Species 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
- C07K14/11—Orthomyxoviridae, e.g. influenza virus
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16171—Demonstrated in vivo effect
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16211—Influenzavirus B, i.e. influenza B virus
- C12N2760/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16211—Influenzavirus B, i.e. influenza B virus
- C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16211—Influenzavirus B, i.e. influenza B virus
- C12N2760/16271—Demonstrated in vivo effect

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Virology (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Immunology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Pulmonology (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Mycology (AREA)
Epidemiology (AREA)
Microbiology (AREA)
Gastroenterology & Hepatology (AREA)
Communicable Diseases (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Oncology (AREA)
Transplantation (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

NO20083416A 2006-02-07 2008-08-04 Peptidsekvenser og preparater NO20083416L (no)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GB0602416A GB0602416D0 (en)	2006-02-07	2006-02-07	Peptide sequences and compositions
GBGB0613977.8A GB0613977D0 (en)	2006-02-07	2006-07-13	Peptide sequences and compositions
PCT/GB2007/000383 WO2007091030A2 (en)	2006-02-07	2007-02-05	Peptide sequences and compositions

Publications (1)

Publication Number	Publication Date
NO20083416L true NO20083416L (no)	2008-11-07

Family

ID=38109631

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20083416A NO20083416L (no)	2006-02-07	2008-08-04	Peptidsekvenser og preparater

Country Status (23)

Country	Link
US (10)	US8475802B2 (he)
EP (6)	EP2383285B1 (he)
JP (1)	JP5603551B2 (he)
KR (1)	KR20080100441A (he)
CN (3)	CN102807608B (he)
AP (1)	AP2646A (he)
AT (1)	ATE534660T1 (he)
AU (1)	AU2007213562A1 (he)
BR (1)	BRPI0707543B8 (he)
CA (1)	CA2641602A1 (he)
DK (4)	DK2383284T3 (he)
EA (1)	EA017387B1 (he)
ES (4)	ES2790730T3 (he)
GB (1)	GB0613977D0 (he)
HK (1)	HK1249115A1 (he)
IL (2)	IL193232A (he)
MX (1)	MX2008010113A (he)
NO (1)	NO20083416L (he)
NZ (1)	NZ570553A (he)
PL (4)	PL2383284T3 (he)
PT (1)	PT1991563E (he)
SG (1)	SG169392A1 (he)
WO (1)	WO2007091030A2 (he)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0408164D0 (en)	2004-04-13	2004-05-19	Immune Targeting Systems Ltd	Antigen delivery vectors and constructs
GB0716992D0 (en) *	2007-08-31	2007-10-10	Immune Targeting Systems Its L	Influenza antigen delivery vectors and constructs
GB0613977D0 (en)	2006-02-07	2006-08-23	Peptcell Ltd	Peptide sequences and compositions
US8097419B2 (en)	2006-09-12	2012-01-17	Longhorn Vaccines & Diagnostics Llc	Compositions and method for rapid, real-time detection of influenza A virus (H1N1) swine 2009
US8080645B2 (en)	2007-10-01	2011-12-20	Longhorn Vaccines & Diagnostics Llc	Biological specimen collection/transport compositions and methods
US9481912B2 (en)	2006-09-12	2016-11-01	Longhorn Vaccines And Diagnostics, Llc	Compositions and methods for detecting and identifying nucleic acid sequences in biological samples
EP2173376B1 (en) *	2007-08-02	2015-03-25	Biondvax Pharmaceuticals Ltd.	Multimeric multiepitope influenza vaccines
US9683256B2 (en)	2007-10-01	2017-06-20	Longhorn Vaccines And Diagnostics, Llc	Biological specimen collection and transport system
US11041215B2 (en)	2007-08-24	2021-06-22	Longhorn Vaccines And Diagnostics, Llc	PCR ready compositions and methods for detecting and identifying nucleic acid sequences
US10004799B2 (en)	2007-08-27	2018-06-26	Longhorn Vaccines And Diagnostics, Llc	Composite antigenic sequences and vaccines
AU2008293504B2 (en)	2007-08-27	2012-04-12	Longhorn Vaccines & Diagnostics, Llc	Immunogenic compositions and methods
US11041216B2 (en)	2007-10-01	2021-06-22	Longhorn Vaccines And Diagnostics, Llc	Compositions and methods for detecting and quantifying nucleic acid sequences in blood samples
CA2861667C (en)	2007-10-01	2017-06-13	Longhorn Vaccines And Diagnostics, Llc	Biological specimen collection and transport system and methods of use
GB0719526D0 (en)	2007-10-05	2007-11-14	Isis Innovation	Compositions and methods
EP2072529A1 (en) *	2007-12-21	2009-06-24	basisnote AG	MHC rapid assay used for the customization of odours
FR2962739B1 (fr) *	2010-07-13	2014-01-31	Univ Claude Bernard Lyon	Souches virales modifiees et procede pour ameliorer la production de semences vaccinales de virus influenza
CA2828068C (en)	2011-02-22	2019-03-19	Biondvax Pharmaceuticals Ltd.	Multimeric multiepitope polypeptides in improved seasonal and pandemic influenza vaccines
WO2013093514A2 (en) *	2011-12-23	2013-06-27	Retroscreen Virology Ltd	Vaccines - peptides
WO2013112916A1 (en)	2012-01-26	2013-08-01	Longhorn Vaccines And Diagnostics, Llc	Composite antigenic sequences and vaccines
JP2018500389A (ja) *	2014-12-10	2018-01-11	華西亞生醫有限公司	効率的な抗体産生のための免疫化に使用される新規なタンパク質構造
WO2016183292A1 (en)	2015-05-14	2016-11-17	Longhorn Vaccines And Diagnostics, Llc	Rapid methods for the extraction of nucleic acids from biological samples
CN106310214A (zh) *	2015-06-30	2017-01-11	中国科学院上海巴斯德研究所	流感病毒蛋白与宿主蛋白cpsf30的相互作用在抑制癌细胞增殖中的应用
JP2019064924A (ja) *	2016-02-24	2019-04-25	Ａｇｃ株式会社	インフルエンザワクチン
KR101888751B1 (ko) *	2016-09-22	2018-09-21	이화여자대학교 산학협력단	인플루엔자 b 백신
AU2017386682A1 (en)	2016-12-28	2019-07-25	Invvax, Inc.	Influenza vaccines
US11576962B2 (en)	2017-12-21	2023-02-14	Green Biomed, Inc.	Cross-immunizing antigen vaccine and method for preparation thereof
CN116134137A (zh) *	2020-07-21	2023-05-16	复尔健有限公司	流感病毒骨架

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4981782A (en)	1987-05-14	1991-01-01	Sri International	Synthetic peptides for diagnosis and prevention of influenza virus infection and their use
US5741493A (en) *	1991-01-24	1998-04-21	Pasteur Merieux Serums Et Vaccins	Vaccine composition against influenza, with synergic effects, containing influenza virus core as an additive
IL101639A0 (en) *	1992-04-17	1992-12-30	Yeda Res & Dev	Recombinant influenza vaccines
AU4998993A (en) *	1992-08-07	1994-03-03	Epimmune, Inc.	Hla binding peptides and their uses
US20040087521A1 (en) *	1993-03-18	2004-05-06	Merck & Co., Inc.	Nucleic acid pharmaceuticals-influenza matrix
IL109664A0 (en)	1993-05-18	1994-08-26	Rijksuniversiteit	Peptides of human influenza virus for use in human t cell response inducing compositions
US6939546B2 (en)	1993-05-21	2005-09-06	The United States Of America As Represented By The Secretary Of The Army	Model for testing immunogenicity of peptides
FR2718452B1 (fr) *	1994-04-06	1996-06-28	Pf Medicament	Elément d'immunogène, agent immunogène, composition pharmaceutique et procédé de préparation.
AU3727895A (en)	1994-09-30	1996-04-26	St. Jude Children's Research Hospital	Nucleic acid encoding mutant matrix proteins useful for attenuation or enhancement of influenza a virus
US7269219B1 (en) *	1997-02-14	2007-09-11	At&T Corp.	Non-linear quantizer for video coding
IL127331A0 (en) *	1998-11-30	1999-09-22	Yeda Res & Dev	Peptide-based vaccine for influenza
JP2001151698A (ja) *	1999-09-10	2001-06-05	Nichiko Pharmaceutical Co Ltd	インフルエンザワクチン
WO2002026252A1 (en)	2000-08-10	2002-04-04	Tsinghua University	A vaccine for influenza virus and its preparation
US7494659B2 (en) *	2000-09-25	2009-02-24	Polymun Scientific Immunbiologische Forschung Gmbh	Live attenuated influenza vaccine
US6906169B2 (en) *	2001-05-25	2005-06-14	United Biomedical, Inc.	Immunogenic peptide composition comprising measles virus Fprotein Thelper cell epitope (MUFThl-16) and N-terminus of β-amyloid peptide
US20050013826A1 (en) *	2002-12-20	2005-01-20	Shneider Alexander M.	Vaccine compositions and methods
US7262045B2 (en) *	2003-02-25	2007-08-28	Medimmune Vaccines, Inc.	Methods of producing influenza vaccine compositions
KR20050114225A (ko) *	2003-03-07	2005-12-05	머크 앤드 캄파니 인코포레이티드	인플루엔자 바이러스 백신
US8592197B2 (en) *	2003-07-11	2013-11-26	Novavax, Inc.	Functional influenza virus-like particles (VLPs)
DE102004052026B4 (de) *	2003-11-07	2015-08-27	Totankako Co., Ltd.	Kollektor
FR2863758B1 (fr) *	2003-12-11	2006-07-14	Centre Nat Rech Scient	Cellule de commande electronique pour diode electroluminescente organique d'afficheur a matrice active, procedes de fonctionnement et afficheur
GB0408164D0 (en)	2004-04-13	2004-05-19	Immune Targeting Systems Ltd	Antigen delivery vectors and constructs
US20060024670A1 (en)	2004-05-18	2006-02-02	Luke Catherine J	Influenza virus vaccine composition and methods of use
CA2606429A1 (en) *	2005-04-21	2006-11-02	University Of Florida Research Foundation, Inc.	Materials and methods for respiratory disease control in canines
US20070116717A1 (en)	2005-08-01	2007-05-24	Shneider Alexander M	Influenza vaccine compositions and methods
WO2007092792A2 (en)	2006-02-02	2007-08-16	Globeimmune, Inc.	Yeast-based vaccine for inducing an immune response
GB0613977D0 (en) *	2006-02-07	2006-08-23	Peptcell Ltd	Peptide sequences and compositions

2006
- 2006-07-13 GB GBGB0613977.8A patent/GB0613977D0/en not_active Ceased
2007
- 2007-02-05 JP JP2008553817A patent/JP5603551B2/ja active Active
- 2007-02-05 BR BRPI0707543A patent/BRPI0707543B8/pt not_active IP Right Cessation
- 2007-02-05 MX MX2008010113A patent/MX2008010113A/es active IP Right Grant
- 2007-02-05 PL PL11157382T patent/PL2383284T3/pl unknown
- 2007-02-05 SG SG201100861-2A patent/SG169392A1/en unknown
- 2007-02-05 AP AP2008004571A patent/AP2646A/xx active
- 2007-02-05 CN CN201210252429.0A patent/CN102807608B/zh not_active Expired - Fee Related
- 2007-02-05 PT PT07712678T patent/PT1991563E/pt unknown
- 2007-02-05 DK DK11157382.0T patent/DK2383284T3/en active
- 2007-02-05 DK DK17180723.3T patent/DK3263589T5/da active
- 2007-02-05 CN CN201110311189.2A patent/CN102382179B/zh not_active Expired - Fee Related
- 2007-02-05 AU AU2007213562A patent/AU2007213562A1/en not_active Abandoned
- 2007-02-05 EP EP11157383.8A patent/EP2383285B1/en active Active
- 2007-02-05 ES ES17180723T patent/ES2790730T3/es active Active
- 2007-02-05 PL PL07712678T patent/PL1991563T3/pl unknown
- 2007-02-05 EP EP11157382.0A patent/EP2383284B1/en active Active
- 2007-02-05 CA CA002641602A patent/CA2641602A1/en not_active Abandoned
- 2007-02-05 ES ES11157382.0T patent/ES2611034T3/es active Active
- 2007-02-05 US US12/278,728 patent/US8475802B2/en not_active Expired - Fee Related
- 2007-02-05 KR KR1020087021658A patent/KR20080100441A/ko not_active Ceased
- 2007-02-05 PL PL11157383T patent/PL2383285T3/pl unknown
- 2007-02-05 EP EP17180723.3A patent/EP3263589B1/en active Active
- 2007-02-05 EP EP17210264.2A patent/EP3320918A3/en not_active Withdrawn
- 2007-02-05 EA EA200870237A patent/EA017387B1/ru not_active IP Right Cessation
- 2007-02-05 DK DK11157383.8T patent/DK2383285T3/en active
- 2007-02-05 EP EP07712678A patent/EP1991563B1/en not_active Revoked
- 2007-02-05 EP EP19192958.7A patent/EP3620463A1/en not_active Ceased
- 2007-02-05 NZ NZ570553A patent/NZ570553A/xx not_active IP Right Cessation
- 2007-02-05 WO PCT/GB2007/000383 patent/WO2007091030A2/en not_active Ceased
- 2007-02-05 CN CN2007800079350A patent/CN101395176B/zh not_active Expired - Fee Related
- 2007-02-05 AT AT07712678T patent/ATE534660T1/de active
- 2007-02-05 DK DK07712678.7T patent/DK1991563T3/da active
- 2007-02-05 ES ES11157383.8T patent/ES2635590T3/es active Active
- 2007-02-05 PL PL17180723T patent/PL3263589T3/pl unknown
- 2007-02-05 ES ES07712678T patent/ES2374841T3/es active Active
2008
- 2008-08-04 IL IL193232A patent/IL193232A/he active IP Right Grant
- 2008-08-04 NO NO20083416A patent/NO20083416L/no not_active Application Discontinuation
2012
- 2012-05-07 US US13/465,940 patent/US8444995B2/en active Active
2013
- 2013-05-30 US US13/906,232 patent/US9446116B2/en active Active
2016
- 2016-08-08 US US15/231,347 patent/US9889191B2/en active Active
2017
- 2017-04-23 IL IL251867A patent/IL251867B/he active IP Right Grant
2018
- 2018-01-08 US US15/865,214 patent/US10279032B2/en active Active
- 2018-01-22 US US15/876,781 patent/US10335480B2/en active Active
- 2018-07-03 HK HK18108547.1A patent/HK1249115A1/en unknown
2019
- 2019-03-07 US US16/295,488 patent/US10765734B2/en active Active
- 2019-08-14 US US16/540,811 patent/US20190365883A1/en not_active Abandoned
2020
- 2020-09-04 US US17/013,000 patent/US11439702B2/en active Active
2022
- 2022-09-09 US US17/931,017 patent/US20230233660A1/en not_active Abandoned

Also Published As

Publication number	Publication date
WO2007091030A3 (en)	2007-11-08
DK2383284T3 (en)	2016-12-12
US10765734B2 (en)	2020-09-08
EP3263589A3 (en)	2018-02-14
US9889191B2 (en)	2018-02-13
US20170028053A1 (en)	2017-02-02
US20190201519A1 (en)	2019-07-04
US8475802B2 (en)	2013-07-02
CA2641602A1 (en)	2007-08-16
US10279032B2 (en)	2019-05-07
CN101395176B (zh)	2013-02-06
JP5603551B2 (ja)	2014-10-08
US11439702B2 (en)	2022-09-13
ES2635590T3 (es)	2017-10-04
US20180147277A1 (en)	2018-05-31
EP3320918A2 (en)	2018-05-16
IL193232A0 (en)	2009-02-11
DK3263589T5 (da)	2020-05-25
EP2383284A2 (en)	2011-11-02
US8444995B2 (en)	2013-05-21
US20100047275A1 (en)	2010-02-25
EP1991563A2 (en)	2008-11-19
EP3320918A3 (en)	2018-08-01
US9446116B2 (en)	2016-09-20
ES2790730T3 (es)	2020-10-29
US20130243804A1 (en)	2013-09-19
BRPI0707543B1 (pt)	2020-11-24
IL251867A0 (he)	2017-06-29
WO2007091030A2 (en)	2007-08-16
EP2383285B1 (en)	2017-07-12
ES2374841T3 (es)	2012-02-22
ATE534660T1 (de)	2011-12-15
US20200397889A1 (en)	2020-12-24
DK3263589T3 (da)	2020-05-11
EP3263589A2 (en)	2018-01-03
AP2008004571A0 (en)	2008-08-31
ES2611034T3 (es)	2017-05-04
BRPI0707543B8 (pt)	2021-05-25
US10335480B2 (en)	2019-07-02
EP2383285A2 (en)	2011-11-02
EP2383285A3 (en)	2012-05-16
IL193232A (he)	2017-05-29
KR20080100441A (ko)	2008-11-18
NZ570553A (en)	2012-08-31
EA017387B1 (ru)	2012-12-28
EP3263589B1 (en)	2020-03-25
PL2383285T3 (pl)	2017-11-30
CN101395176A (zh)	2009-03-25
CN102382179B (zh)	2014-01-22
GB0613977D0 (en)	2006-08-23
MX2008010113A (es)	2009-01-19
AU2007213562A2 (en)	2008-11-20
EP2383284A3 (en)	2012-05-30
PL3263589T3 (pl)	2020-07-13
EP3620463A1 (en)	2020-03-11
PL1991563T3 (pl)	2012-02-29
BRPI0707543A2 (pt)	2011-05-03
JP2009526028A (ja)	2009-07-16
DK1991563T3 (da)	2012-01-23
CN102807608A (zh)	2012-12-05
PT1991563E (pt)	2011-12-29
US20120219575A1 (en)	2012-08-30
EA200870237A1 (ru)	2009-06-30
IL251867B (he)	2018-06-28
SG169392A1 (en)	2011-03-30
EP1991563B1 (en)	2011-11-23
CN102382179A (zh)	2012-03-21
AP2646A (en)	2013-04-17
CN102807608B (zh)	2015-01-21
EP2383284B1 (en)	2016-08-24
US20190365883A1 (en)	2019-12-05
PL2383284T3 (pl)	2017-07-31
US20180185470A1 (en)	2018-07-05
AU2007213562A1 (en)	2007-08-16
DK2383285T3 (en)	2017-08-28
US20230233660A1 (en)	2023-07-27
HK1249115A1 (en)	2018-10-26

Legal Events

Date	Code	Title	Description
2014-09-22	FC2A	Withdrawal, rejection or dismissal of laid open patent application

Publication	Publication Date	Title
NO20083416L (no)	2008-11-07	Peptidsekvenser og preparater
MX2024012403A (es)	2024-11-08	Novedoso vector del subtipo f del virus adenoasociado (aav) y usos de este
MX2010012999A (es)	2012-03-07	Vacuna de vesícula de membrana externa nativa multivalente del meningococo, método para su fabricación y uso.
PH12021550030A1 (en)	2021-09-20	Nucleotide sequences encoding peptide antigens of sars-cov-2 virus and use thereof
NZ603348A (en)	2014-05-30	Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof
MX358725B (es)	2018-09-03	Antigenos prostaticos de consenso, molecula de acido nucleico que los codifica y vacuna y usos que los comprenden.
MX2011006846A (es)	2011-09-09	Virus de fiebre porcina clasico recombinante (csfv) comprendiendo una proteina e2 modificada y metodos para generar dicho csfv.
NO20082149L (no)	2008-07-16	Hundeinfluensavirus og relaterte sammensetninger og fremgangsmater for bruk
NZ718006A (en)	2017-06-30	Vaccine and methods to reduce campylobacter infection
RU2011154363A (ru)	2013-07-20	Комбинации клад rrgb пневмококков
NZ594268A (en)	2013-05-31	Grass peptides for vaccine
NO20062948L (no)	2006-08-23	Promotere for ekspresjon i modifisert vaccinia-virus Ankara
NO20083576L (no)	2008-12-10	Peptider av regulatoriske eller hjelpeproteiner av HIV, samt sammensetninger og anvendelser derav
DE60323634D1 (de)	2008-10-30	Nichtimmunsuppressive immunogene oder vakzinzusammensetzung enthaltend ein mutiertes e7-protein vom humanen papilloma-virus hpv-16
NZ603854A (en)	2015-03-27	West nile virus vaccine
DE602005018615D1 (de)	2010-02-11	Schen polypeptiden und deren verwendung als impfstoffe und in der immuntherapie
EP2504029A4 (en)	2013-08-07	COMPOSITIONS, METHODS AND USES FOR THE EXPRESSION OF PEPTIDES ASSOCIATED WITH ENTEROBACTERIA
NO20084348L (no)	2008-12-23	Vaksine for terapeutiske eller profylaktisk behandling av myastenia gravis
GB2429711A (en)	2007-03-07	Heart and skeletal muscle inflammation (HSMI) virus
ATE466876T1 (de)	2010-05-15	Immunogene konstrukte
NO20085201L (no)	2009-03-05	Rekombinante novirhabdoviruser og deres anvendelse
NZ591738A (en)	2013-05-31	Non-typhoidal salmonella vaccines comprising a polypeptide which is an outer membrane protein d of non typoidal salmonella
JP2017526366A5 (he)	2018-09-27
UA100496C2 (ru)	2013-01-10	Последовательность пептида, который является иммуногенным для позвоночного, и композиция
BR112013009276A2 (pt)	2019-09-24	peptídeos de c18orf54 e vacinas incluindo os mesmos